Cargando…

Type II natural killer T cells foster the antitumor activity of CpG-oligodeoxynucleotides

Type II natural killer T (NKT) cells in cancer immunity are typically associated with suppression of tumor immunosurveillance through secretion of IL-13. We previously demonstrated that CpG oligonucleotide therapy activated Type II NKT cells to produce T helper type 1 (Th1) rather than T helper type...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhao, Jie, Bagchi, Sreya, Wang, Chyung-Ru
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2014
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4091550/ https://www.ncbi.nlm.nih.gov/pubmed/25057452 http://dx.doi.org/10.4161/onci.28977

Ejemplares similares

Effect of CpG ODN on monocytic myeloid derived suppressor cells
por: Shirota, Hidekazu, et al.
Publicado: (2012)

DEC-205 is a cell surface receptor for CpG oligonucleotides
por: Caminschi, Irina, et al.
Publicado: (2013)

CpG oligodeoxynucleotides as mucosal adjuvants
por: Iho, Sumiko, et al.
Publicado: (2015)

Forging a potent vaccine adjuvant: CpG ODN/cationic peptide nanorings
por: Gungor, Bilgi, et al.
Publicado: (2014)

CpG oligodeoxynucleotides potentiate the antitumor activity of anti-BST2 antibody
por: Hiramatsu, Kosuke, et al.
Publicado: (2015)

Production of epitope-specific antibodies using peptide-CpG-ODN-liposome complex without carriers and their application as a cancer vaccine in mice
por: Lee, YoungHee, et al.
Publicado: (2012)

Neonate Intestinal Immune Response to CpG Oligodeoxynucleotide Stimulation
por: Lacroix-Lamandé, Sonia, et al.
Publicado: (2009)

Systemic Administration of CpG Oligodeoxynucleotide and Levamisole as Adjuvants for Gene-Gun-Delivered Antitumor DNA Vaccines
por: Šmahel, Michal, et al.
Publicado: (2011)

Orphan CpG islands as alternative promoters
por: Sarda, Shrutii, et al.
Publicado: (2017)

CpG-oligodeoxynucleotides exert remarkable antitumor activity against diffuse malignant peritoneal mesothelioma orthotopic xenografts
por: De Cesare, Michelandrea, et al.
Publicado: (2016)

Structure-dependent immunostimulatory effect of CpG oligodeoxynucleotides and their delivery system
por: Hanagata, Nobutaka
Publicado: (2012)

A Novel C Type CpG Oligodeoxynucleotide Exhibits Immunostimulatory Activity In Vitro and Enhances Antitumor Effect In Vivo
por: Li, Tete, et al.
Publicado: (2020)

Immunosurveillance of senescent cancer cells by natural killer cells
por: Iannello, Alexandre, et al.
Publicado: (2014)

Cooperative Stimulation of Dendritic Cells by Cryptococcus neoformans Mannoproteins and CpG Oligodeoxynucleotides
por: Dan, Jennifer M., et al.
Publicado: (2008)

CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies
por: Hanagata, Nobutaka
Publicado: (2017)

Synergistic oligodeoxynucleotide strongly promotes CpG-induced interleukin-6 production
por: Nigar, Shireen, et al.
Publicado: (2017)

A CpG oligodeoxynucleotide enhances the immune response to rabies vaccination in mice
por: Yu, Pengcheng, et al.
Publicado: (2018)

Lipid Nanoparticles Potentiate CpG-Oligodeoxynucleotide-Based Vaccine for Influenza Virus
por: Shirai, Seiki, et al.
Publicado: (2020)

CpG Oligodeoxynucleotides for Anticancer Monotherapy from Preclinical Stages to Clinical Trials
por: Zhang, Zhongkun, et al.
Publicado: (2021)

ATM activation mediates anticancer immunosurveillance by natural killer and T cells
por: Tang, Melissa LF, et al.
Publicado: (2013)

Natural killer T cell strategies to combat Epstein–Barr virus infection
por: Priatel, John J, et al.
Publicado: (2014)

Tumor vaccine composed of C-class CpG oligodeoxynucleotides and irradiated tumor cells induces long-term antitumor immunity
por: Cerkovnik, Petra, et al.
Publicado: (2010)

CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity
por: Chu, Rose S., et al.
Publicado: (1997)

CpG-Oligodeoxynucleotide Treatment Protects against Ionizing Radiation-Induced Intestine Injury
por: Zhang, Chao, et al.
Publicado: (2013)

Effects of CpG oligodeoxynucleotide 1826 on acute radiation-induced lung injury in mice
por: Li, Xuan, et al.
Publicado: (2016)

Immunostimulatory Activities of CpG-Oligodeoxynucleotides in Teleosts: Toll-Like Receptors 9 and 21
por: Lai, Chao-Yang, et al.
Publicado: (2019)

Role of Kupffer cells in liver injury induced by CpG oligodeoxynucleotide and flucloxacillin in mice
por: Gao, Yuying, et al.
Publicado: (2020)

Anti-SARS-CoV immunity induced by a novel CpG oligodeoxynucleotide
por: Bao, Musheng, et al.
Publicado: (2006)

CpG oligodeoxynucleotides inhibit the proliferation and osteoclastic differentiation of RAW264.7 cells
por: Zheng, Yi, et al.
Publicado: (2020)

KLRG1(+) natural killer cells protect against pulmonary metastatic disease by immunosurveillance
por: Renner, Philipp, et al.
Publicado: (2014)

A critical role for natural killer cells in dendritic cell-based anticancer immunotherapy
por: McLellan, Alexander D
Publicado: (2014)

Non-classical MHC Class I molecules regulating natural killer cell function
por: Smyth, Mark J., et al.
Publicado: (2013)

Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype
por: Kellner, Christian, et al.
Publicado: (2013)

Antitumor efficacy of multi-target in situ vaccinations with CpG oligodeoxynucleotides, anti-OX40, anti-PD1 antibodies, and aptamers
por: Proskurina, Anastasia S., et al.
Publicado: (2023)

CpG Oligodeoxynucleotide Developed to Activate Primate Immune Responses Promotes Antitumoral Effects in Combination with a Neoantigen-Based mRNA Cancer Vaccine
por: Li, Qin, et al.
Publicado: (2021)

Treatment with Class A CpG Oligodeoxynucleotides in Cats with Naturally Occurring Feline Parvovirus Infection: A Prospective Study
por: Ferri, Filippo, et al.
Publicado: (2020)

Driving Natural Killer cells toward the melanoma tumor battlefield: Autophagy as a valuable therapeutic target
por: Noman, Muhammad Zaeem, et al.
Publicado: (2018)

Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers
por: Cooper, Curtis L, et al.
Publicado: (2008)

CpG oligodeoxynucleotide stimulates production of anti-neutrophil cytoplasmic antibodies in ANCA associated vasculitis
por: Hurtado, Plinio R, et al.
Publicado: (2008)

Intratracheal synthetic CpG oligodeoxynucleotide causes acute lung injury with systemic inflammatory response
por: Tasaka, Sadatomo, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_kq3nk37f4rbjseua6jnd7bqi8h